Industry News
Biotechnology Industry News
Generate:Biomedicines is hoping to…
Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead antibody through respiratory disease trials.
Gilead has struck a deal to buy…
Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.
MoonLake Immunotherapeutics has…
MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a midstage win in a type of arthritis.
In an effort to battle against…
In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America with a focus on
Ionis Pharmaceuticals has pulled…
Ionis Pharmaceuticals has pulled the plug on an early investigational treatment for Alzheimer’s disease in people with Down syndrome, marking another setback for a group of patients who are both at higher risk for the
After an FDA rejection of its…
After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it zeroes in on obesity.
Four years after he resigned as…
Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai, M.D., has taken up a similar role at Daiichi Sankyo.
As Candel Therapeutics gears up…
As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW Investments has stepped in with $100 million to bankroll the launch.
The Swiss drugmaker has plucked an…
The Swiss drugmaker has plucked an experienced scientist from Down Under to lead its early research efforts. Hematologist Mark Dawson, M.D., Ph.D., an expert in cancer epigenetics, will now head up Roche’s pharma research and
Novartis has jettisoned an…
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease.
Breaking ground: iRegene’s…
Breaking ground: iRegene’s NouvNeu001 hits first U.S. dosing in Parkinson’s Phase IIa, while NouvNeu004 starts enrollment in China MSA trial. Pushing forward off-the-shelf iPSC therapies on a global scale.
Politico has reported that the…
Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator.
Johnson & Johnson has paused…
Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease candidate, leaving analysts to speculate that recruitment challenges may be the culprit.
Sanofi has backed the $75 million…
Sanofi has backed the $75 million series B of a rhinovirus-focused biotech helmed by a former FDA acting commissioner.
Demyelinating diseases, including…
Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and escalating burden. Each of these conditions afflicts approximately three million individuals worldwide.
In a deal with Theriva Biologics…
In a deal with Theriva Biologics potentially worth as much as $36 million, Rasayana Therapeutics has gained a gastrointestinal asset called SYN-020.
Only a couple of months ago,…
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. But the biotech has found a new lease on life—and a new lead drug—via a merger with
Unnatural Products is proving to…
Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.
The FDA has accepted Moderna’s…
The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026-27 flu season.
EIR Biopharma is hoping to bring…
EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug.